Tags

Type your tag names separated by a space and hit enter

Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort.
Neurodegener Dis. 2010; 7(1-3):183-6.ND

Abstract

BACKGROUND

We reported a significant 67% reduction in the hazard risk of incident Alzheimer's disease (AD) with elective statin use in the AD Anti-inflammatory Prevention Trial (ADAPT), without a reduction in risk of incident mild cognitive impairment (MCI).

OBJECTIVE

To assess if cholesterol levels are associated with cognitive performance and determine if statin use alters cognitive performance after onset of MCI.

DESIGN

Fractionated cholesterol levels, neurological and cognitive status were evaluated annually. Comparisons of non-LLA (lipid-lowering agent) users or statin-LLA users were performed blind to the ADAPT medication randomization. Pearson's correlations were validated using a time-dependent linear mixed model.

RESULTS

The MMSE performance significantly declined over time in non-LLA users, and, after adjusting for this, a significant positive correlation between MMSE and HDL was identified (p = 0.0002). A negative correlation between total and LDL cholesterol, and immediate and delayed recall of the Rivermead paragraph was significant (total cholesterol, p < 0.003; LDL, p < 0.02). Pilot data suggest a positive signal on delayed recall of both the Hopkins word list and Rivermead paragraph with deterioration in the non-LLA users and improvement in the statin users after conversion to MCI.

CONCLUSION

Cholesterol levels may be associated with differential performance on the MMSE and measures of learning or memory. The trend for improved delayed recall in statin users with MCI compared to non-LLA users with MCI may have contributed to the reduced hazards risk of incident AD without reducing the risk of MCI.

Authors+Show Affiliations

Roberts Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, Ariz., USA. alina.solomon@uku.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20224282

Citation

Sparks, D Larry, et al. "Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use After Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort." Neuro-degenerative Diseases, vol. 7, no. 1-3, 2010, pp. 183-6.
Sparks DL, Kryscio RJ, Connor DJ, et al. Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neurodegener Dis. 2010;7(1-3):183-6.
Sparks, D. L., Kryscio, R. J., Connor, D. J., Sabbagh, M. N., Sparks, L. M., Lin, Y., & Liebsack, C. (2010). Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. Neuro-degenerative Diseases, 7(1-3), 183-6. https://doi.org/10.1159/000295660
Sparks DL, et al. Cholesterol and Cognitive Performance in Normal Controls and the Influence of Elective Statin Use After Conversion to Mild Cognitive Impairment: Results in a Clinical Trial Cohort. Neurodegener Dis. 2010;7(1-3):183-6. PubMed PMID: 20224282.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort. AU - Sparks,D Larry, AU - Kryscio,Richard J, AU - Connor,Donald J, AU - Sabbagh,Marwan N, AU - Sparks,Lisa M, AU - Lin,Yushun, AU - Liebsack,Carolyn, Y1 - 2010/03/12/ PY - 2010/3/13/entrez PY - 2010/3/13/pubmed PY - 2010/7/22/medline SP - 183 EP - 6 JF - Neuro-degenerative diseases JO - Neurodegener Dis VL - 7 IS - 1-3 N2 - BACKGROUND: We reported a significant 67% reduction in the hazard risk of incident Alzheimer's disease (AD) with elective statin use in the AD Anti-inflammatory Prevention Trial (ADAPT), without a reduction in risk of incident mild cognitive impairment (MCI). OBJECTIVE: To assess if cholesterol levels are associated with cognitive performance and determine if statin use alters cognitive performance after onset of MCI. DESIGN: Fractionated cholesterol levels, neurological and cognitive status were evaluated annually. Comparisons of non-LLA (lipid-lowering agent) users or statin-LLA users were performed blind to the ADAPT medication randomization. Pearson's correlations were validated using a time-dependent linear mixed model. RESULTS: The MMSE performance significantly declined over time in non-LLA users, and, after adjusting for this, a significant positive correlation between MMSE and HDL was identified (p = 0.0002). A negative correlation between total and LDL cholesterol, and immediate and delayed recall of the Rivermead paragraph was significant (total cholesterol, p < 0.003; LDL, p < 0.02). Pilot data suggest a positive signal on delayed recall of both the Hopkins word list and Rivermead paragraph with deterioration in the non-LLA users and improvement in the statin users after conversion to MCI. CONCLUSION: Cholesterol levels may be associated with differential performance on the MMSE and measures of learning or memory. The trend for improved delayed recall in statin users with MCI compared to non-LLA users with MCI may have contributed to the reduced hazards risk of incident AD without reducing the risk of MCI. SN - 1660-2862 UR - https://www.unboundmedicine.com/medline/citation/20224282/Cholesterol_and_cognitive_performance_in_normal_controls_and_the_influence_of_elective_statin_use_after_conversion_to_mild_cognitive_impairment:_results_in_a_clinical_trial_cohort_ L2 - https://www.karger.com?DOI=10.1159/000295660 DB - PRIME DP - Unbound Medicine ER -